Discover how ADAMAS helped a sponsor prepare for inspection using a targeted risk-based approach
Our latest case study highlights how ADAMAS Consulting supported a leading pharmaceutical company in proactively identifying high-risk sites during a global Phase III oncology trial—aligning with ICH E6 (R3) guidelines.
See how ADAMAS leveraged expert-led strategy and Cyntegrity’s advanced risk analytics to remotely assess data quality across 50 investigator sites. The result: site-specific risks were identified early, enabling timely corrective actions and improving inspection outcomes.
Download the full case study to learn how ADAMAS empowers sponsors to implement effective risk-based strategies, enhance GCP compliance, and reduce inspection risk in complex clinical trials.
